Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(8):575; doi:10.1093/jnci/93.8.575
© 2001 by Oxford University Press
This Article
Right arrow Extract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 8, 575, April 18, 2001
© 2001 Oxford University Press

NEWS

Major Institute of Medicine Panel Recommendations

• That FDA and insurers cover the costs of clinical trials for breast cancer screening tests

• That NCI create a permanent infrastructure for reviewing breast cancer screening modalities, specifically supporting clinical trials every 10 to 15 years

• That FDA alter the market approval process for new breast cancer screening technologies, setting a higher bar for use as a screening tool than for use in diagnosis

• That NCI examine the benefit that older women get from screening mammography


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?